Clinical Trial

Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies, in Part 1, the tolerability of KK2845 will be evaluated to determine the maximum tolerated dose (MTD). In Part 2, additional data will be collected by administering KK2845 at dose levels for which tolerability has been confirmed.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-02; most recent amendment 2026-06-29.
Trial Details
NCT Number NCT06812104
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions Relapsed or Refractory AML and Other Hematologic Malignancies
Enrollment 156 participants
Start Date 2024-10-10
Primary Completion 2031-11-30 (estimated)
Study Completion 2031-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-01